Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Day One Biopharmaceuticals reports robust Q3 earnings and eyes growth opportunities

Day One Biopharmaceuticals delivered strong Q3 earnings, showcasing commercial success and financial stability, with OJEMDA leading revenue generation.
Challenges lie in maintaining patient starts and addressing physician feedback, while opportunities in trials and partnerships offer avenues for growth and innovation.
Overall, Day One Biopharmaceuticals' performance reflects a promising trajectory with a solid foundation for future expansion and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allogene Therapeutics Inc

Immunocore Holdings

Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

Day One Biopharmaceuticals' key asset, tovorafenib, shows promise in treating pediatric low-grade glioma, with ongoing phase 3 trials aiming to expand its use. DAWN's financial health is strong, with $422.8 million in cash and equivalents, ensuring sustainability for over two years despite a net loss excluding licensing revenue. The company's deep cash reserves and promising pipeline, including the new DAY301 agent, provide a solid foundation for future growth and drug development.

Day One Biopharmaceuticals: Sales Figures In The Crosshairs

BRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time.

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D.

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3 at 3:00 p.m. EST.

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 136.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Samuel Blackman - Co-Founder and Head, R&D Charles York - COO and CFO Conference Call Participants Anupam Rama - JPMorgan Joe Catanzaro - Piper Sandler Andrea Newkirk - Goldman Sachs Soumit Roy - Jones Research Alec Stranahan - Bank of America Ami Fadia - Needham & Company Andres Maldonado - H.C. Wainwright Operator Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals' Third Quarter of 2024 Financial and Operating Results Conference Call.

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript

Day One Biopharmaceuticals, Inc. (DAWN) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to loss of $0.54 per share a year ago.

Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates

Achieved $20.1 million in OJEMDA TM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, October 30, 4:30 p.m. Eastern Time BRISBANE, Calif.

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

The average of price targets set by Wall Street analysts indicates a potential upside of 140.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet

BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Wednesday, October 30, 2024 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2024.

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Robinhood

NEXTracker Inc

When volatility strikes the stock market as it sets new highs, investors get nervous. Wild swings in price can often signal a market top.

Bank of America Says Buy These 3 Stocks for a Double-Digit Rally

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.61 per share a year ago.

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates

Achieved $8.2 million in OJEMDA TM (tovorafenib) net product revenues in initial 2 months of launch

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $175.0 million, before deducting placement agent fees and other expenses.

Day One Announces Oversubscribed $175.0 Million Private Placement

PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Day One Biopharmaceuticals (Nasdaq: DAWN) (Day One), announced today a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma (pLGG), the most common form of childhood brain cancer, i and any future indications developed by Day One.

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.

Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up

Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

BRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it sold its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. The Company was awarded the PRV following the U.S. Food and Drug Administration (FDA) accelerated approval of OJEMDA™ (tovorafenib).

Day One Announces Sale of Priority Review Voucher for $108 Million

OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Co

Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

Day One Biopharmaceuticals is a leader in pediatric oncology, with a focus on addressing the unmet needs of pediatric cancer patients. The company has a strong financial position, with enough cash to fund operations through 2026, and is progressing through clinical trials with promising results. Day One's lead product candidate, tovorafenib, has the potential to redefine the standard of care for pediatric low-grade glioma, pending regulatory approval.

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time.

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting

News for Day One Biopharmaceuticals Stock (DAWN)